Xilio Therapeutics (XLO) Net Income towards Common Stockholders (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$14.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 1.59% year-over-year to -$14.1 million; the trailing twelve-month figure through Mar 2026 stood at -$42.4 million (up 26.35% YoY), and the FY2025 full-year result was -$167.4 million, up 3.28% from the prior year.
• Net Income towards Common Stockholders retreated to -$14.1 million in Q1 2026, from -$11.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.0 million in Q3 2025 to a low of -$24.8 million in Q2 2022.
• A 5-year average of -$17.0 million and a median of -$17.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders retreated 28.13% in 2022 and soared 86.56% in 2025, its largest moves.
• Tracing XLO's Net Income towards Common Stockholders over 5 years: stood at -$24.4 million in 2022, then gained by 21.33% to -$19.2 million in 2023, then increased by 27.6% to -$13.9 million in 2024, then climbed by 14.72% to -$11.9 million in 2025, then fell by 19.12% to -$14.1 million in 2026.
• Business Quant data shows XLO's Net Income towards Common Stockholders at -$14.1 million in Q1 2026, -$11.9 million in Q4 2025, and -$2.0 million in Q3 2025.